Comparative Pharmacology
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus DOCIVYX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus DOCIVYX.
CEFTAROLINE FOSAMIL vs DOCIVYX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
Docivyx is a docetaxel formulation; it binds to tubulin, promoting assembly of microtubules and inhibiting depolymerization, leading to cell cycle arrest and apoptosis.
600 mg IV every 12 hours infused over 1 hour
75 mg/m2 intravenously over 1 hour every 3 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
Terminal elimination half-life is 24-48 hours; prolonged with hepatic impairment.
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Primarily hepatic metabolism followed by biliary excretion; <10% excreted unchanged in urine.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic